Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies

• Published in: Journal of neuro-oncology 2021-03, Vol.152 (1), p.1-13
• Main Authors: Haddad, Alexander F., Young, Jacob S., Mummaneni, Nikhil V., Kasahara, Noriyuki, Aghi, Manish K.
• Format: Article
• Language: English
• Subjects: Brain cancer; Cell death; Clinical trials; Glioblastoma; Immune clearance; Immune response; Immune system; Immunotherapy; Medicine; Medicine & Public Health; Neurology; Oncology; Oncolysis; Patients; Suicide genes; Topic Review; Tumor cells; Viruses
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-020-03684-5

Introduction The treatment for glioblastoma (GBM) has remained unchanged for the past decade, with only minimal improvements in patient survival. As a result, novel treatments are needed to combat this devastating disease. Immunotherapies are treatments that stimulate the immune system to attack tumor cells and can be either local or systemically delivered. Viral treatments can lead to direct tumor cell death through their natural lifecycle or through the delivery of a suicide gene, with the potential to generate an anti-tumor immune response, making them interesting candidates for combinatorial treatment with immunotherapy. Methods We review the current literature surrounding the interactions between oncolytic viruses and the immune system as well as the use of oncolytic viruses combined with immunotherapies for the treatment of GBM. Results Viral therapies have exhibited preclinical efficacy as single-agents and are being investigated in that manner in clinical trials. Oncolytic viruses have significant interactions with the immune system, although this can also vary depending on the strain of virus. Combinatorial treatments using both oncolytic viruses and immunotherapies have demonstrated promising preclinical findings. Conclusions Studies combining viral and immunotherapeutic treatment modalities have provided exciting results thus far and hold great promise for patients with GBM. Additional studies assessing the clinical efficacy of these treatments as well as improved preclinical modeling systems, safety mechanisms, and the balance between treatment efficacy and immune-mediated viral clearance should be considered.